ARTICLE
6 February 2020

PMPRB Extends Comment Deadline For Draft Guidelines; Related Presentations Now Published

SB
Smart & Biggar

Contributor

Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients. Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights. As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
As previously reported, the Patented Medicine Prices Review Board (PMPRB) recently released draft Guidelines operationalizing the amended Patented Medicines Regulations ...
Canada Intellectual Property

As previously reported, the Patented Medicine Prices Review Board (PMPRB) recently released draft Guidelines operationalizing the amended Patented Medicines Regulations for consultation.  The consultation period has been extended (a second time) to February 14, 2020.  Submissions are to be sent to PMPRB.Consultations.CEPMB@pmprb-cepmb.gc.ca.  The PMPRB continues to consult with stakeholders in the meantime.

The PMPRB has also released the presentations from its Patentee Webinar on January 17, 2020, as well as the earlier Industry Forum held December 9, 2019 and Civil Society Forum held December 10, 2019.

Of note, the Patentee Webinar:

  • highlights distinctions between the current and proposed Guidelines;
  • provides two case studies of how the maximum rebated price and maximum list price will work in practice;
  • provides detail on filing requirements under the new Guidelines; and
  • includes further details on transition, including for grandfathered and "gap" medicines, and what to expect after the July 1, 2020 coming into force.

The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More